全文获取类型
收费全文 | 2200篇 |
免费 | 158篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 66篇 |
儿科学 | 102篇 |
妇产科学 | 29篇 |
基础医学 | 229篇 |
口腔科学 | 43篇 |
临床医学 | 256篇 |
内科学 | 457篇 |
皮肤病学 | 5篇 |
神经病学 | 155篇 |
特种医学 | 68篇 |
外科学 | 365篇 |
综合类 | 61篇 |
预防医学 | 189篇 |
眼科学 | 76篇 |
药学 | 127篇 |
中国医学 | 2篇 |
肿瘤学 | 132篇 |
出版年
2022年 | 22篇 |
2021年 | 42篇 |
2020年 | 25篇 |
2019年 | 43篇 |
2018年 | 36篇 |
2017年 | 30篇 |
2016年 | 41篇 |
2015年 | 38篇 |
2014年 | 49篇 |
2013年 | 54篇 |
2012年 | 102篇 |
2011年 | 108篇 |
2010年 | 71篇 |
2009年 | 42篇 |
2008年 | 98篇 |
2007年 | 96篇 |
2006年 | 105篇 |
2005年 | 101篇 |
2004年 | 86篇 |
2003年 | 76篇 |
2002年 | 93篇 |
2001年 | 74篇 |
2000年 | 94篇 |
1999年 | 83篇 |
1998年 | 31篇 |
1997年 | 27篇 |
1996年 | 19篇 |
1995年 | 24篇 |
1994年 | 12篇 |
1993年 | 14篇 |
1992年 | 70篇 |
1991年 | 62篇 |
1990年 | 59篇 |
1989年 | 40篇 |
1988年 | 27篇 |
1987年 | 48篇 |
1986年 | 36篇 |
1985年 | 31篇 |
1984年 | 15篇 |
1983年 | 17篇 |
1982年 | 12篇 |
1981年 | 11篇 |
1980年 | 14篇 |
1979年 | 35篇 |
1978年 | 18篇 |
1977年 | 10篇 |
1972年 | 14篇 |
1971年 | 16篇 |
1970年 | 10篇 |
1966年 | 13篇 |
排序方式: 共有2362条查询结果,搜索用时 15 毫秒
71.
72.
Nancy Cardinez Leif E. Lovblom Johnny-Wei Bai Evan Lewis Alon Abraham Daniel Scarr Julie A. Lovshin Yuliya Lytvyn Genevieve Boulet Mohammed A. Farooqi Andrej Orszag Alanna Weisman Hillary A. Keenan Michael H. Brent Narinder Paul Vera Bril David Z. Cherney Bruce A. Perkins 《Journal of diabetes and its complications》2018,32(7):660-664
Aim
Neuropathy and neuropathic pain are common complications of type 1 diabetes (T1D). We aimed to determine if sex-specific differences in neuropathic pain are present in adults with longstanding T1D.Methods
Canadians with ≥50?years of T1D (n?=?361) completed health history questionnaires that included assessment of neuropathy (defined by Michigan Neuropathy Screening Instrument questionnaire components ≥3; NEUROPATHYMNSI-Q) and neuropathic pain. Multivariable logistic regression was used to determine sex-differences in neuropathic pain controlling for neuropathy.Results
Participants had mean age 66?±?9?years, median diabetes duration 53[51,58] years, mean HbA1c 7.5?±?1.0%, and 207(57%) were female. Neuropathic pain was present in 128(36%) of all participants, more prevalent among those with NEUROPATHYMNSI-Q compared to those without [96(63%) vs. 31(15%), p?<?0.001], and more prevalent in females compared to males [87(42%) vs. 41(27%), p?=?0.003]. Independent of the presence of NEUROPATHYMNSI-Q and other factors, female sex was associated with the presence of neuropathic pain [OR 2.68 (95% CI 1.4–5.0), p?=?0.002].Conclusions
We demonstrated a novel sex-specific difference in neuropathic pain in females compared to males with longstanding T1D, independent of the presence of neuropathy. Further research using more objective measures of neuropathy than the MNSI is justified to further understand this sex-specific difference. 相似文献73.
Masao Omata Shuhei Nishiguchi Yoshiyuki Ueno Hitoshi Mochizuki Namiki Izumi Fusao Ikeda Hidenori Toyoda Osamu Yokosuka Kazushige Nirei Takuya Genda Takeji Umemura Tetsuo Takehara Naoya Sakamoto Yoichi Nishigaki Kunio Nakane Nobuo Toda Tatsuya Ide Mikio Yanase Keisuke Hino Bing Gao Kimberly L. Garrison Hadas Dvory‐Sobol Akinobu Ishizaki Masa Omote Diana Brainard Steven Knox William T. Symonds John G. McHutchison Hiroshi Yatsuhashi Masashi Mizokami 《Journal of viral hepatitis》2014,21(11):762-768
Genotype 2 hepatitis C virus (HCV) accounts for up to 30% of chronic HCV infections in Japan. The standard of care for patients with genotype 2 HCV – peginterferon and ribavirin for 24 weeks – is poorly tolerated, especially among older patients and those with advanced liver disease. We conducted a phase 3, open‐label study to assess the efficacy and safety of an all‐oral combination of the NS5B polymerase inhibitor sofosbuvir and ribavirin in patients with chronic genotype 2 HCV infection in Japan. We enrolled 90 treatment‐naïve and 63 previously treated patients at 20 sites in Japan. All patients received sofosbuvir 400 mg plus ribavirin (weight‐based dosing) for 12 weeks. The primary endpoint was sustained virologic response at 12 weeks after therapy (SVR12). Of the 153 patients enrolled and treated, 60% had HCV genotype 2a, 11% had cirrhosis, and 22% were over the aged 65 or older. Overall, 148 patients (97%) achieved SVR12. Of the 90 treatment‐naïve patients, 88 (98%) achieved SVR12, and of the 63 previously treated patients, 60 (95%) achieved SVR12. The rate of SVR12 was 94% in patients with cirrhosis and in those aged 65 and older. No patients discontinued study treatment due to adverse events. The most common adverse events were nasopharyngitis, anaemia and headache. Twelve weeks of sofosbuvir and ribavirin resulted in high rates of SVR12 in treatment‐naïve and previously treated patients with chronic genotype 2 HCV infection. The treatment was safe and well tolerated by patients, including the elderly and those with cirrhosis. 相似文献
74.
Sue Manley Russell Keenan Helen Campbell Mark Caswell Barry Pizer 《British journal of haematology》2014,164(3):462-464
75.
77.
78.
Smit HJ Keenan E Kovacs EM Wiseman SA Mela DJ Rogers PJ 《International journal of obesity (2005)》2012,36(9):1222-1228
Background/Objectives:Fabuless (Olibra) is a commercially structured lipid emulsion, claimed to be a food ingredient that is effective for food intake and appetite reduction. The present study assessed its efficacy in a yoghurt-based mini-drink undergoing low or minimal food manufacturing (thermal and shear) processes.Subjects/Methods:Study 1: Twenty-four healthy volunteers (16 female, 8 male; age: 18-47 years; body mass index (BMI): 17-28?kg?m(-2)) took part in a randomised, placebo-controlled, double-blind parallel crossover trial. Consumption of a minimally processed 'preload' mini-drink (containing two different doses of Fabuless or a control fat) at 2?h after breakfast was followed by appetite and mood ratings, and food intake measured in ad libitum meals at 3 and 7?h post consumption of the preload. Study 2: As Study 1 (16 female, 8 male; age: 20-54 years; BMI: 21-30?kg?m(-2)). A chilled, virtually unprocessed, preload breakfast mini-drink (containing minimally processed Fabuless or a control fat) was provided 5?min after a standardised breakfast, followed by appetite and mood ratings, and food intake measured in ad libitum meals at 4 and 8?h post consumption of the preload.Results:The structured lipid emulsion tested had no significant effect on the primary measures of food intake or appetite.Conclusions:Even when exposed to minimal food-manufacturing conditions, Fabuless showed no efficacy on measures of appetite and food intake. 相似文献
79.
80.
Anna M. Badowska-Kozakiewicz Maria Sobol Janusz Patera Wojciech Koz?owski 《Archives of Medical Science》2013,9(3):466-471